THC Therapeutics (THCT) Stock Statistics & Valuation Metrics
Total Valuation
THC Therapeutics has a market cap or net worth of $87.93K. The enterprise value is $908.02B.
- Market Cap
- $87.93K
- Enterprise Value
- $908.02B
Share Statistics
THC Therapeutics has 43,966,150 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 43,966,150
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
THC Therapeutics’s return on equity (ROE) is 0.12 and return on invested capital (ROIC) is 20.42%.
- Return on Equity (ROE)
- 0.12
- Return on Assets (ROA)
- -29.79
- Return on Invested Capital (ROIC)
- 20.42%
- Return on Capital Employed (ROCE)
- 0.15
- Revenue Per Employee
- 0
- Profits Per Employee
- -387.04K
- Employee Count
- 1
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of THC Therapeutics is -0.17. THC Therapeutics’s PEG ratio is 0.00.
- PE Ratio
- -0.17
- PS Ratio
- 0.00
- PB Ratio
- -0.02
- Price to FCF
- -0.91
- Price to Operating Cash Flow
- -0.77
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, THC Therapeutics had revenue of 0 and earned -387.04K in profits. Earnings per share was -0.01.
- Revenue
- 0
- Gross Profit
- -1,393
- Operating Income
- -493.91K
- Pretax Income
- -387.04K
- Net Income
- -387.04K
- EBITDA
- -492.52K
- Earnings Per Share (EPS)
- -0.01
Cash Flow
In the last 12 months, operating cash flow was -182.51K and capital expenditures 0, giving a free cash flow of -182.51K billion.
- Operating Cash Flow
- -182.51K
- Free Cash Flow
- -182.51K
- Free Cash Flow per Share
- -0.00
Dividends & Yields
THC Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -109.90%
- Earnings Yield
- -589.89%
Stock Price Statistics
- Beta
- -38.35
- 52-Week Price Change
- -36.67%
- 50-Day Moving Average
- 0.02
- 200-Day Moving Average
- 0.02
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- ―
Financial Position
THC Therapeutics as a current ratio of 0.00, with Debt / Equity ratio of -23.91%
- Current Ratio
- 0.00
- Quick Ratio
- 0.00
- Debt to Market Cap
- 1125.82
- Net Debt to EBITDA
- -1.61
- Interest Coverage Ratio
- -6.21
Taxes
In the past 12 months, THC Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
THC Therapeutics EV to EBITDA ratio is -1.76, with an EV/FCF ratio of -10.17.
- EV to Sales
- 0.00
- EV to EBITDA
- -1.76
- EV to Free Cash Flow
- -10.17
- EV to Operating Cash Flow
- -10.17
Balance Sheet
THC Therapeutics has $849.00 in cash and marketable securities with $731.79K in debt, giving a net cash position of -$730.94K billion.
- Cash & Marketable Securities
- $849.00
- Total Debt
- $731.79K
- Net Cash
- -$730.94K
- Net Cash Per Share
- -$0.02
- Tangible Book Value Per Share
- -$0.09
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for THC Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- 0
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―
